General
Preferred name
DORAMAPIMOD
Synonyms
BIRB-796 ()
BIRB 0796 ()
BIRB 796 ()
Doramapimod (BIRB-796) ()
GW839464X ()
Doramapimod (BIRB 796) ()
BIRB 796 BS ()
BIRB-796 BS ()
BIRB0796BS ()
P&D ID
PD003343
CAS
285983-48-4
1283526-53-3
Tags
available
free of charge
probe
drug candidate
Drug indication
psoriasis
Inflammatory bowel disease
Drug Status
investigational
Max Phase
2.0
Probe info
Probe type
experimental probe
Probe sources
Chemical Probes.org
High-quality chemical probes
opnMe Portal
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Doramapimod is an allosteric p38 MAP kinase inhibitor . (GtoPdb)
DESCRIPTION Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38¦Á=38 nM, for p38¦Â=65 nM, for p38¦Ã=200 nM, and for p38¦Ä=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM[1][2].
PRICE 50
MOA Inhibitor (Chemical Probes.org)
DESCRIPTION Doramapimod (BIRB 796) is a potent inhibitor of the p38 mitogen activated protein kinase (MAPK). The compound shows anti-inflammatory properties at nanomolar concentrations in cell cultures, which are based on the suppression of TNF-α production. Efficacy of the compound was also shown in animal models of endotoxin-stimulated TNF-α release and collagen-induced arthritis. (opnMe Portal)
DESCRIPTION inhibitor of p38 MAPK (Informer Set)
DESCRIPTION Potent and selective SMYD2 inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70. (TargetMol Bioactive Compound Library)
Cell lines
100
Organisms
0
Compound Sets
29
AdooQ Bioactive Compound Library
A10148
Axon Medchem Screening Library
1358
Cayman Chemical Bioactives
10460
ChEMBL Drugs
CHEMBL103667
Chemical Probes.org
doramapimod
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB03044
DrugMAP
DM6BU7N
EU-OPENSCREEN Bioactive Compound Library
EOS101373
EUbOPEN Chemogenomics Library
EUB0001517
Guide to Pharmacology
5668
High-quality chemical probes
PD003343
Informer Set
660412
Ki Database
BIRB-796
LINCS compound set
10169-101
10169-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL103667
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL103667
MedChem Express Bioactive Compound Library
HY-10320
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
opnMe Portal
doramapimod-birb796
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
BIRB-796-(Doramapimod)
TargetMol Bioactive Compound Library
T6277
Tocris Bioactive Compound Library
5989
Welcome Trust Cancer Drugs
1042
External IDs
37
Properties
(calculated by RDKit )
Molecular Weight
527.29
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
5.99
TPSA
80.65
Fraction CSP3
0.35
Chiral centers
0.0
Largest ring
6.0
QED
0.31
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
MAPK11
MAPK14
Androgen receptor (ANDR)
MAPK11, MAPK12, MAPK13, MAPK14
JNK,p38 MAPK,Raf,Src
MAPK12
MAPK13
Raf
p38α
Compound status
probe
Pathway
JNK and p38 signaling
Autophagy
MAPK
MAPK/ERK Pathway
Primary Target
p38 MAPK
MOA
Inhibitor
SAPK2 (p38beta) Inhibitors
Inhibitors of Signal Transduction Pathways
p38 MAPK Inhibitors
p38 MAPK inhibitor
Member status
member
Target class
Kinase
Target subclass
CMGC
Recommended Cell Concentration
None
Source data